Costantino Di Carlo
e-mail: cdicarlo AT unina.it
website: www.unina.it
affiliation: Università di Napoli Federico II
research area(s): Neuroscience
Courses:
- Neurosciences
- Molecular Oncology and Endocrinology
- Molecular Pathology and Pathophysiology
Date of birth: 26/03/1962
Place of birth: Napoli
Present position: Associate Professor of Gynecology and Obstetrics at the Dipartimento di Neuroscienze e Scienze Riproduttive e Odontostomatologiche - University Federico II in Naples
Graduated in Medicine cum laude in 1986 at the University Federico II in Naples
Specialized in Obstetrics and Gynaecology cum laude in 1990 at the University Federico II in Naples
From october 1989 to november 1990 Research Fellow in Reproductive Medicine at the Middlesex Hospital in London with Prof. H.S. Jacobs.
From 1990 to 2002 he worked at the University Hospital Federico II in Naples with different appointments.
From 2002 to 2006 he was Ricercatore in Obstetrics and Gynecology at the University Federico II in Naples.
From march 2006 he is Associate Professor in Obstetrics and Gynecology at the same University.
Author of more than 100 scientific papers published on peer reviewed international journals.
Member of the Board of the European Society for Contraception.
Member of the Board of the Italian Society of Contraception.
Place of birth: Napoli
Present position: Associate Professor of Gynecology and Obstetrics at the Dipartimento di Neuroscienze e Scienze Riproduttive e Odontostomatologiche - University Federico II in Naples
Graduated in Medicine cum laude in 1986 at the University Federico II in Naples
Specialized in Obstetrics and Gynaecology cum laude in 1990 at the University Federico II in Naples
From october 1989 to november 1990 Research Fellow in Reproductive Medicine at the Middlesex Hospital in London with Prof. H.S. Jacobs.
From 1990 to 2002 he worked at the University Hospital Federico II in Naples with different appointments.
From 2002 to 2006 he was Ricercatore in Obstetrics and Gynecology at the University Federico II in Naples.
From march 2006 he is Associate Professor in Obstetrics and Gynecology at the same University.
Author of more than 100 scientific papers published on peer reviewed international journals.
Member of the Board of the European Society for Contraception.
Member of the Board of the Italian Society of Contraception.
Reproductive medicine:
Postmenopausal hormone replacement therapy
Contraception
Urogynecology:
Mini-invasive surgery for the treatment of urinary stress incontinence
Postmenopausal hormone replacement therapy
Contraception
Urogynecology:
Mini-invasive surgery for the treatment of urinary stress incontinence
1: Di Carlo C, Sansone A, De Rosa N, Gargano V, Tommaselli GA, Nappi C, Bifulco
G. Impact of an implantable steroid contraceptive (etonogestrel-releasing
implant) on quality of life and sexual function: a preliminary study. Gynecol
Endocrinol. 2013 Oct 16.
2: Di Carlo C, Iannotti G, Sparice S, Chiacchio MP, Greco E, Tommaselli GA, Nappi C. The role of a personalized dietary intervention in managing gestational weight gain: a prospective, controlled study in a low-risk antenatal population. Arch Gynecol Obstet. 2013 Oct 16.
3: Di Carlo C, Gargano V, Sparice S, Tommaselli GA, Bifulco G, Nappi C. Effects
of an oral contraceptive containing estradiol valerate and dienogest on
circulating androgen levels and acne in young patients with PCOS: an
observational preliminary study. Gynecol Endocrinol. 2013 Dec;29(12):1048-50.
4: DeCensi A, Bonanni B, Maisonneuve P, Serrano D, Omodei U, Varricchio C,
Cazzaniga M, Lazzeroni M, Rotmensz N, Santillo B, Sideri M, Cassano E, Belloni C,Muraca M, Segnan N, Masullo P, Costa A, Monti N, Vella A, Bisanti L, D'Aiuto G, Veronesi U; Italian HOT Study Group. A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study. Ann Oncol. 2013 Nov;24(11):2753-60.
5: Di Carlo C, Gargano V, Sparice S, Tommaselli GA, Bifulco G, Schettino D, Nappi C. Short-term effects of an oral contraceptive containing oestradiol valerate and dienogest on bone metabolism and bone mineral density: an observational,preliminary study. Eur J Contracept Reprod Health Care. 2013 Oct;18(5):388-93.
6: Tommaselli GA, D'Afiero A, Di Carlo C, Formisano C, Fabozzi A, Nappi C.
Tension-free vaginal tape-O and -Secur for the treatment of stress urinary
incontinence: a thirty-six-month follow-up single-blind, double-arm, randomized
study. J Minim Invasive Gynecol. 2013 Mar-Apr;20(2):198-204.
7: Tommaselli GA, D'Afiero A, Di Carlo C, Formisano C, Fabozzi A, Nappi C.
Efficacy of a modified technique for TVT-O positioning: a twelve-month,
randomized, single-blind, multicenter, non-inferiority study. Eur J Obstet
Gynecol Reprod Biol. 2013 Apr;167(2):225-9.
8: Tommaselli GA, Di Carlo C, Formisano C, Fabozzi A, Nappi C. Vaginal delivery
following single incision sling (TVT-Secur) for female stress urinary
incontinence. J Obstet Gynaecol Res. 2013 Feb;39(2):608-10.
9: Bifulco G, Di Spiezio Sardo A, De Rosa N, Greco E, Spinelli M, Di Carlo C,
Tommaselli GA, Nappi C. The use of an oral contraceptive containing estradiol
valerate and dienogest before office operative hysteroscopy: a feasibility study.Gynecol Endocrinol. 2012 Dec;28(12):949-55.
10: Nappi C, Bifulco G, Tommaselli GA, Gargano V, Di Carlo C. Hormonal
contraception and bone metabolism: a systematic review. Contraception. 2012
Dec;86(6):606-21.
11: Di Carlo C, Savoia F, Gargano V, Sparice S, Bifulco G, Nappi C. Successful
pregnancy complicated by spontaneous, familial, recurrent ovarian
hyperstimulation syndrome: report of two cases. Gynecol Endocrinol. 2013
Oct;29(10):897-900.
G. Impact of an implantable steroid contraceptive (etonogestrel-releasing
implant) on quality of life and sexual function: a preliminary study. Gynecol
Endocrinol. 2013 Oct 16.
2: Di Carlo C, Iannotti G, Sparice S, Chiacchio MP, Greco E, Tommaselli GA, Nappi C. The role of a personalized dietary intervention in managing gestational weight gain: a prospective, controlled study in a low-risk antenatal population. Arch Gynecol Obstet. 2013 Oct 16.
3: Di Carlo C, Gargano V, Sparice S, Tommaselli GA, Bifulco G, Nappi C. Effects
of an oral contraceptive containing estradiol valerate and dienogest on
circulating androgen levels and acne in young patients with PCOS: an
observational preliminary study. Gynecol Endocrinol. 2013 Dec;29(12):1048-50.
4: DeCensi A, Bonanni B, Maisonneuve P, Serrano D, Omodei U, Varricchio C,
Cazzaniga M, Lazzeroni M, Rotmensz N, Santillo B, Sideri M, Cassano E, Belloni C,Muraca M, Segnan N, Masullo P, Costa A, Monti N, Vella A, Bisanti L, D'Aiuto G, Veronesi U; Italian HOT Study Group. A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study. Ann Oncol. 2013 Nov;24(11):2753-60.
5: Di Carlo C, Gargano V, Sparice S, Tommaselli GA, Bifulco G, Schettino D, Nappi C. Short-term effects of an oral contraceptive containing oestradiol valerate and dienogest on bone metabolism and bone mineral density: an observational,preliminary study. Eur J Contracept Reprod Health Care. 2013 Oct;18(5):388-93.
6: Tommaselli GA, D'Afiero A, Di Carlo C, Formisano C, Fabozzi A, Nappi C.
Tension-free vaginal tape-O and -Secur for the treatment of stress urinary
incontinence: a thirty-six-month follow-up single-blind, double-arm, randomized
study. J Minim Invasive Gynecol. 2013 Mar-Apr;20(2):198-204.
7: Tommaselli GA, D'Afiero A, Di Carlo C, Formisano C, Fabozzi A, Nappi C.
Efficacy of a modified technique for TVT-O positioning: a twelve-month,
randomized, single-blind, multicenter, non-inferiority study. Eur J Obstet
Gynecol Reprod Biol. 2013 Apr;167(2):225-9.
8: Tommaselli GA, Di Carlo C, Formisano C, Fabozzi A, Nappi C. Vaginal delivery
following single incision sling (TVT-Secur) for female stress urinary
incontinence. J Obstet Gynaecol Res. 2013 Feb;39(2):608-10.
9: Bifulco G, Di Spiezio Sardo A, De Rosa N, Greco E, Spinelli M, Di Carlo C,
Tommaselli GA, Nappi C. The use of an oral contraceptive containing estradiol
valerate and dienogest before office operative hysteroscopy: a feasibility study.Gynecol Endocrinol. 2012 Dec;28(12):949-55.
10: Nappi C, Bifulco G, Tommaselli GA, Gargano V, Di Carlo C. Hormonal
contraception and bone metabolism: a systematic review. Contraception. 2012
Dec;86(6):606-21.
11: Di Carlo C, Savoia F, Gargano V, Sparice S, Bifulco G, Nappi C. Successful
pregnancy complicated by spontaneous, familial, recurrent ovarian
hyperstimulation syndrome: report of two cases. Gynecol Endocrinol. 2013
Oct;29(10):897-900.
Project Title:
Project Title:
Evaluation of the effects of an oral contraceptive containing ethinylestradiol and drospirenone on body composition and adipokine levels
Background
Improvement of safety and tolerability has been one of the main objectives in the development of hormonal contraception over the last 20 years. One of the means for achieving this goal is the development of new progestogens. The ideal progestogen should be, from a pharmacological point of view, identical to natural progesterone. The most used progestogens in hormonal contraceptives, i.e. 19-nortestosterone- and 17-hydroxyprogesterone-derived progestins, are more or less similar to natural progesterone for their progestational, estrogenic and androgenic properties, but they all lack antimineralcortidoid activity. This could be the reason for weight gain, water retention and increased blood pressure observed with the use of hormonal contraceptives.
Objective of the study
Our recent study (23) showed that a DRSP-containing COC increases the serum levels of adiponectin, suggesting a possible negative effect on body fat.
The recent data on obese rhesus monkeys (24) showed that COCs may reduce body fat content.
Taking into account both these evidences, we hypothesize that DRPS may have a favourable effect in obese women reducing fat mass and, possibly, changing the secretory pattern of several adipokines
Therefore, aim of the present study is to provide a preliminary evaluation of the impact of a DRPS-containing CO on body composition, resting metabolic rate, adiponectin, leptin and IL-6 levels in overweight/obese women, in order to allow a further randomized, double blind study vs. other therapies.
Improvement of safety and tolerability has been one of the main objectives in the development of hormonal contraception over the last 20 years. One of the means for achieving this goal is the development of new progestogens. The ideal progestogen should be, from a pharmacological point of view, identical to natural progesterone. The most used progestogens in hormonal contraceptives, i.e. 19-nortestosterone- and 17-hydroxyprogesterone-derived progestins, are more or less similar to natural progesterone for their progestational, estrogenic and androgenic properties, but they all lack antimineralcortidoid activity. This could be the reason for weight gain, water retention and increased blood pressure observed with the use of hormonal contraceptives.
Objective of the study
Our recent study (23) showed that a DRSP-containing COC increases the serum levels of adiponectin, suggesting a possible negative effect on body fat.
The recent data on obese rhesus monkeys (24) showed that COCs may reduce body fat content.
Taking into account both these evidences, we hypothesize that DRPS may have a favourable effect in obese women reducing fat mass and, possibly, changing the secretory pattern of several adipokines
Therefore, aim of the present study is to provide a preliminary evaluation of the impact of a DRPS-containing CO on body composition, resting metabolic rate, adiponectin, leptin and IL-6 levels in overweight/obese women, in order to allow a further randomized, double blind study vs. other therapies.
Project Title:
Pathophysiology of the hypothalamic-pituitary-ovarian axis.